Who is sponsoring NCT01432496?

NCT01432496 is sponsored by San Gerardo Hospital.

What condition does NCT01432496 study?

NCT01432496 studies Postoperative Pain.

What drugs are being tested in NCT01432496?

Interventions: Ropivacaine 150 mg, saline 15 ml.

What is the status of NCT01432496?

NCT01432496 is currently TERMINATED.

Last reviewed 2013-02-22 · How we verify

A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline

NCT01432496 Phase 3 TERMINATED

The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 150 mg produces better postoperative pain control than Saline nebulization after laparoscopic colectomy.

Details

Lead sponsor	San Gerardo Hospital
Phase	Phase 3
Status	TERMINATED
Enrolment	130
Start date	2011-09
Completion	2012-12

Conditions

Postoperative Pain

Interventions

Ropivacaine 150 mg
saline 15 ml

Primary outcomes

Postoperative pain — 72 hours
Numeric Ranking Scale (NRS 0 to 10 points) at rest (static NRS) and after a deep inspiration or cough (dynamic NRS) in PACU and at 6, 24, 48 and 72 hours after the discharge from PACU.

Countries

Italy